Moderna continues to be on an upward trend

By: Miguel A. Rodriguez

09:45, 14 September 2020

The idea of a vaccine is getting closer and closer to becoming a reality.

The week debuted with good news for and from Moderna.  

The company announced that it secured a funding of $472 million from the US government to further develop a COVID-19 vaccine. The money will be used to start a late-stage clinical trial, with an extended Phase III study of the vaccine.

It is the second funding that Moderna receives from the government. Back in April, it got $483 million from the Biomedical Advanced Research and Development Authority to continue its research amid positive data collected from the Phase I trial.

The company is moving on with its Phase III trial, which will consist of up to 30,000 people. It will be a placebo-controlled trial, conducted with the National Institute of Allergy and Infectious Diseases. The endgame is the prevention of symptomatic COVID-19, while the virus contraction and preventing the severe forms which require hospitalization will be resolved along the way. 

Today the share price gained more than 11%. Pushed by the fact that it is the front-runner for developing a viable COVID-19 vaccine, the stock price increased more than 270% this year, while USA500 slid 0.4%. 

Read more about the pharmaceutical companies here! Register and check out our Corona Blend!


Share this article

The information presented herein is prepared by and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.                                                                                                                            Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation.Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.